Therefore, insulin is typically administered only in conjunction with intravenous glucose infusion, using low doses (0.1–0.2 IU per kg body weight) of regular insulin given subcutaneously or intramuscularly immediately following glucose infusion, with close monitoring of blood glucose concentrations at 2–4-h intervals to detect and manage potential hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.